The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.
Filip Janku
Research Funding - Novartis
Yasuhiro Oki
No relevant relationships to disclose
Gerald Steven Falchook
No relevant relationships to disclose
Vivek Subbiah
No relevant relationships to disclose
Aung Naing
No relevant relationships to disclose
Vivianne Marie Velez Bravo
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Jason R. Westin
No relevant relationships to disclose
Cesar Nunez
No relevant relationships to disclose
Luis Fayad
No relevant relationships to disclose
Sattva Swarup Neelapu
No relevant relationships to disclose
Larry W. Kwak
No relevant relationships to disclose
Elizabeth J. Shpall
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Tamara Barnes
No relevant relationships to disclose
Winnie S. Liang
No relevant relationships to disclose
Bodour Salhia
No relevant relationships to disclose
Funda Meric-Bernstam
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose
Michelle A. Fanale
No relevant relationships to disclose